FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. financials
Regeneron Pharmaceuticals, Inc. (REGN) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $2,885.6 | $3,105.9 | $2,730 | $2,488.2 | $3,118.1 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $16,071.7 | $12,172.9 | $13,117.2 | $14,202 | $14,342.9 | $17,708 | $18,737.3 |
| % Growth | 89.1% | -24.3% | 7.8% | 8.3% | 1.0% | 23.5% | 5.8% |
| Gross Profit | $14,298.6 | $11,372.9 | $12,185.1 | $13,114.7 | $13,202.1 | - | - |
| % Margin | 89.0% | 93.4% | 92.9% | 92.3% | 92.0% | - | - |
| EBITDA | $9,233 | $5,080.3 | $4,468.1 | $4,473.6 | $4,121.6 | - | - |
| % Margin | 57.4% | 41.7% | 34.1% | 31.5% | 28.7% | - | - |
| Net Income | $8,075.3 | $4,338.4 | $3,953.6 | $4,412.6 | $4,504.9 | - | - |
| % Margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% | - | - |
| Diluted EPS | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | $59.88 | $63.43 |
| % Growth | 135.8% | -46.9% | -9.0% | 10.3% | 8.2% | 44.4% | 5.9% |
| Operating Cash Flow | $7,081.3 | $5,014.9 | $4,594 | $4,420.5 | $4,978.9 | - | - |
| CapEx | $551.9 | $590.1 | $718.6 | $755.9 | $898.4 | - | - |
| Free Cash Flow | $6,529.4 | $4,424.8 | $3,875.4 | $3,664.6 | $4,080.5 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $16,071.7 | $12,172.9 | $13,117.2 | $14,202 | $14,342.9 | $17,708 | $18,737.3 |
| Gross Profit | $14,298.6 | $11,372.9 | $12,185.1 | $13,114.7 | $13,202.1 | - | - |
| EBITDA | $9,233 | $5,080.3 | $4,468.1 | $4,473.6 | $4,121.6 | - | - |
| Net Income | $8,075.3 | $4,338.4 | $3,953.6 | $4,412.6 | $4,504.9 | - | - |
| Diluted EPS | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | $59.88 | $63.43 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,885.6 | $3,105.9 | $2,730 | $2,488.2 | $3,118.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $1,980 | $1,981.4 | $1,982.9 | $1,984.4 | $1,985.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7,081.3 | $5,014.9 | $4,594 | $4,420.5 | $4,978.9 |
| Capital Expenditure | $551.9 | $590.1 | $718.6 | $755.9 | $898.4 |
| Free Cash Flow | $6,529.4 | $4,424.8 | $3,875.4 | $3,664.6 | $4,080.5 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 89.1% | -24.3% | 7.8% | 8.3% | 1.0% |
| Gross Margin | 89.0% | 93.4% | 92.9% | 92.3% | 92.0% |
| EBITDA Margin | 57.4% | 41.7% | 34.1% | 31.5% | 28.7% |
| Net Margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| FCF Margin | 40.6% | 36.3% | 29.5% | 25.8% | 28.4% |
| Diluted EPS Growth | 135.8% | -46.9% | -9.0% | 10.3% | 8.2% |
Get the REGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.